[Survival of 5-fluorouracil-treated stomach cancer patients in the far-advanced stages].
Umder study was the survival rate in 73 patients treated routinely with 5-fluoruracil for recurrences and metastases of gastric cancer. The survival of 33 patients, treated with the clinical effect proved to be reliably higher than that in 40 patients in whom no effect was gained (the time of 50% survival was 7.1 and 2.4 months accordingly). The compared groups of patients did not differ reliably in such prognostic factors as the tumor spread to the onset of chemotherapy and duration of the interval since the primary operation till tumor progression. It is concluded that the longer survival in patients treated with the effect is due to 5-fluoruracil administration.
D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D005472:Fluorouracil / Q000627:therapeutic use*; D005743:Gastrectomy; D006801:Humans; D007700:Kinetics; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000401:mortality; D013274:Stomach Neoplasms / Q000188:drug therapy / Q000401:mortality*; D013997:Time Factors
D005472:Fluorouracil
Vyzhivaemost' lechennykh 5-ftoruratsilom bol'nykh rakom zheludka daleko zashedshikh stadiĭ.